NARA Discovery
Article Details
← Back to Search Results
Journal Article

A novel pharmacological mechanism of anti-cancer drugs that induce pyroptosis

Haohao Guo; Ziyang Wang; Runsheng Ma; Xin Chen; Hongqiang Li; Yifeng Tang; Gongbo Du; Yifei Zhang; Detao Yin
Inflammopharmacology · Vol. 31, Issue 2 · pp. 745-754 · 2023

Abstract

Pyroptosis is an inflammasome-induced lytic form of programmed cell death, and its main effect involves the release of inflammatory mediators when a cell dies, resulting in an inflammatory response in the body. The key to pyroptosis is the cleavage of GSDMD or other gasdermin families. Some drugs can cause cleavage GSDMD or other gasdermin members cause pyroptosis and suppress cancer growth and development. This review explores several drugs that may induce pyroptosis, thereby contributing to tumor treatment. Pyroptosis-inducing drugs, such as arsenic, platinum, and doxorubicin, were used originally in cancer treatment. Other pyroptosis-inducing drugs, such as metformin, dihydroartemisinin, and famotidine, were used to control blood glucose, treat malaria, and regulate blood lipid levels and are effective tumor treatments. By summarizing drug mechanisms, we provide a valuable basis for treating cancers by inducing pyroptosis. In future, the use of these drugs may contribute to new clinical treatments.

Bibliographic Information

JournalInflammopharmacology
PublisherSpringer
Publication Date2023-04-01
Publication Year2023
Volume31
Issue2
Pages745-754
Document TypeJournal Article
Print ISSN0925-4692
eISSN1568-5608
DOI10.1007/s10787-023-01148-6

Access Information

NARA Access Coverage1991-01-01~Current
Journal Homepagehttps://www.springer.com/journal/10787
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.